Furthermore, these cells were unable to recruit RAD51 to sites of DNA damage after cisplatin treatment (Fig. 4d, e), which is in line with the data obtained from HBCx-14 tumours (Fig. 3a, b). Here, RAD51 is linked to neoplasm.